Recent studies have reported that PD-L1 is highly expressed in a subset of patients with advanced thyroid cancer, including FTC, and correlates with a higher risk of recurrence and shortened disease-free survival [12, 29]. Here, CD274 is linked to thyroid gland carcinoma.